After anti-HER2 treatment, for the tumor with HER2 amplification, the release of cytokines such as CCL2, CCL21, VEGF, and CXCL1 was downregulated, and the immunosuppressive factors of the tumor microenvironment were improved (50). This evidence concerns the gene ERBB2 and neoplasm.